Collision Tumor of Primary Laryngeal Mucosal Melanoma and Invasive Squamous Cell Carcinoma with IL-17A and CD70 Gene Over-Expression
First Online: 10 August 2010 Received: 21 April 2010 Accepted: 20 July 2010 DOI:
10.1007/s12105-010-0200-8 Cite this article as: Sirikanjanapong, S., Lanson, B., Amin, M. et al. Head and Neck Pathol (2010) 4: 295. doi:10.1007/s12105-010-0200-8 Abstract
The most common primary malignancy of the larynx is the squamous cell carcinoma (SCC). The primary malignant melanoma is quite rare in this location. Less than 60 cases of laryngeal melanomas have been reported to date. To our knowledge, collision primary malignant melanoma and invasive squamous cell carcinoma in the vocal cords has not been reported. We report a 53-year-old male patient who was diagnosed with a collision tumor of laryngeal melanoma and invasive SCC. Multiple Th17 pathway related genes including CTLA-4, IL-17A-F, PLZF, FoxP3, RorγT, CD27, and CD70 were analyzed by reverse transcriptase-polymerase chain reaction (Rt–PCR) in this case. Both IL-17A and CD70 genes were detected in this case of collision tumor. The results may define useful biomarkers for early diagnosis of mucosal melanoma and open an immunotherapeutic field for clinical management with the potential benefit from the immunomodulators that enhance both genes.
Keywords Collision tumor Laryngeal mucosal melanoma Squamous cell carcinoma IL-17A and CD70 genes
Funded by grant number: NIH/NCRR 1UL1RR029893-01.
Marur S, Forastiere AA. Head and neck cancer: changing epidemiology, diagnosis, and treatment. Mayo Clin Proc. 2008;83:489–501.
Barnes L. Surgical pathology of the head and neck, 3rd edn. Informa Healthcare. New York; 2008. pp. 137–160.
Chang AE, Karnell LH, Menck HR. The National Cancer Data Base Report on cutaneous and non cutaneous melanoma. A summary of 84,836 cases from the past decade. Cancer. 1998;83:1664–78.
Wagner M, Morris CG, Werning JW, et al. Mucosal melanoma of the head and neck. Am J Clin Oncol. 2008;31:43–8.
Wenig BM. Laryngeal mucosal malignant melanoma. A clinicopathologic, immunohistochemical, and ultrastructural study in four patients and a review of the article. Cancer. 1995;75:1568–77.
Wang W, Edington HD, Rao UN, et al. Effects of high-dose IGNα2b on regional lymph node metastases of human melanoma: modulation of STAT5, Foxp3, and IL-17. Clin Cancer Res. 2008;14:8314–20.
Patrick RJ, Fenske NA, Messina JL. Primary mucosal melanoma. J Am Acad Dermatol. 2007;56:828–34.
Shah JP, Huvos AG, Strong EW. Mucosal melanomas of the head and neck. Am J Surg. 1977;134:531–5.
Reuter VE, Woodruff JM. Melanoma of the larynx. Laryngoscope. 1986;94:389–93.
Terada T, Saeki N, Toh K, et al. Primary malignant melanoma of the larynx: a case report and review literature. Auris Nasus Larynx. 2007;34:105–10.
Kim H, Park CI. Primary malignant laryngeal melanoma: report of a case with a review of literature. Yonsei Med J. 1982;23:118–22.
Tomidokoro Y, Hayashi R, Yamasaki M, et al. Simultaneous squamous cell carcinoma with leimomyosarcoma of the larynx. Auris Nasus Larynx. 2009;36:239–43.
Medina-Banegas A, Osete-Albaladejo JM, Capitan-Guarnizo A, et al. Double tumor of the larynx: a case report. Eur Arch Otolaryngol. 2003;260:341–3.
Allen AC, Spitz S. Malignant melanoma: a clinicopathological analysis of the criteria for diagnosis and prognosis. Cancer. 1953;6:1–45.
Moore ES, Martin H. Melanoma of the upper respiratory tract and oral cavity. Cancer. 1955;8:1167–76.
Amin HM, Petruzzelli GJ, Husain AN, et al. Primary malignant melanoma of the larynx. Arch Pathol Lab Med. 2001;125:271–3.
Morris LG, Wen YH, Nonaka D, et al. Melanocytic marker in immunohistochemical evaluation of primary mucosal melanoma of the head and neck. Head Neck. 2008;30:771–5.
Muranski P, Boni A, Antony PA, et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood. 2008;112:362–73.
Yamaguchi Y, Fujio K, Shoda H, et al. IL-17B and IL-17C are associated with TNF-α production and contribute to the exacerbation of inflammatory arthritis. J Immunol. 2007;179:7128–36.
von Euw E, Chodon T, Attar N, et al. CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J Transl Med. 2009;7:35.
Cormary C, Gonzalez R, Faye JC, et al. Induction of T-cell antitumor immunity and protection against tumor growth by secretion of soluble human CD70 molecules. Cancer Gene Ther. 2004;11:497–507.
Garley M, Jablonska E, Grabowska SZ, et al. IL-17 family cytokines in neutrophils of patients with oral epithelial squamous cell carcinoma. Neoplasma. 2009;56:96–100.
Langowski JL, Zhang X, Wu L, et al. IL-23 promotes tumour incidence and growth. Nature. 2006;442:461–5.
Overwijk WW, de Visser KE, Tirion FH, et al. Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant. J Immunol. 2006;176:5213–22.
Numasaki M, Watanabe M, Suzuki T, et al. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol. 2005;175:6177–89.
Kryczek I, Wei S, Zou L, et al. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol. 2007;178:6730–3.
Wang L, Yi T, Kortylewski M, et al. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med. 2009;206:1457–64.
Cormary C, Hiver E, Mariamé B, et al. Coexpression of CD40L and CD70 by semiallogenic tumor cells induces anti-tumor immunity. Cancer Gene Ther. 2005;2:963–72.
Couderc B, Zitvogel L, Douin-Echinard V, et al. Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (CD40 ligand) costimulatory molecules in tumor cells. Cancer Gene Ther. 1998;5:163–75.
Snow GB, VanDerEsch EP, Van Sloanten EA. Mucosal melanomas of the head and neck. Head Neck Surg. 1978;1:24–30.